EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease.
Miceli-Richard
Corinne
C
Service de Rhumatologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France. corinne.miceli@bct.aphp.fr
Mariette
Xavier
X
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000473:pathology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000276:immunology* / Q000473:pathology; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008727:Methotrexate / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects / Q000502:physiology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D008727:Methotrexate